Mr. Carter of Georgia (for himself, Ms. Barragán, Mrs. Harshbarger, Mr. Buchanan, Mr. Carter of Louisiana, Mr. Waltz, Ms. DeLauro, Mr. Nehls, Mr. Gooden of Texas, Mr. Crenshaw, and Mr. Fitzpatrick) introduced the following bill; which was referred to the Committee on Energy and Commerce
To amend the Federal Food, Drug, and Cosmetic Act to establish a process for the qualification of nonclinical testing methods to reduce and replace the use of animals in nonclinical research, improve the predictivity of nonclinical testing methods, and reduce development time for a biological product or other drug, and for other purposes.
Diana Harshbarger
(TN); Vern Buchanan
(FL); Troy Carter
(LA); Michael Waltz
(FL); Rosa L. DeLauro
(CT); Troy E. Nehls
(TX); Lance Gooden
(TX); Dan Crenshaw
(TX); Brian K. Fitzpatrick
(PA)
Citations are generated automatically from bibliographic data as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. House. FDA Modernization Act 3.0. H.R. 7248. 118th
Cong., 2nd
sess., Introduced in House February 6, 2024. https://www.govinfo.gov/app/details/BILLS-118hr7248ih.
APA
Congress, House of Representatives (2024, February 6). FDA Modernization Act 3.0 (H.R. 7248 (IH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-118hr7248ih.
MLA
United States, Congress, House of Representatives. FDA Modernization Act 3.0. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-118hr7248ih. 118th Congress, H.R. 7248, Introduced in House 6 Feb. 2024.
Bluebook
H.R.7248 - 118th Congress (2023-2024): FDA Modernization Act 3.0, H.R.7248, 118th Cong. (2024), https://www.govinfo.gov/app/details/BILLS-118hr7248ih.
